drugset / Trial / NCT00738738
6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open-label, multi-site, 6-month study of an investigational compound in elderly outpatients, age 65 years old or above, to assess the long-term safety and tolerability of the compound in the treatment of elderly subjects with Generalized Anxiety Disorder (GAD).
Timeline
- Start
- 2009-01
- Primary completion
- 2009-02
- Completion
- 2009-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMAGABALIN | Other / unclassified | 50 mg | Oral |
| Subject | IMAGABALIN | Other / unclassified | 100 mg | Oral |
| Subject | IMAGABALIN | Other / unclassified | 350 mg | Oral |